Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

By Yahoo! Finance | Nov 8, 2024 at 02:17 AM EST

Camille L. Bedrosian, Chief Medical Officer, discussed the phase III trial design for PBH, emphasizing a 90 mg dose with primary endpoint of composite level II and III hypoglycemia. Data is expected in 2026, building on successful phase II results.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.